Global Neoantigen Targeted Therapies Market Research Report by Target Disease Indication, by Immunotherapy Type, by Route of Administration - Global Forecast to 2029 - Business Impact of COVID-19

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Neoantigen Targeted Therapies Market


Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have not previously been recognized by the host's immune system. In 2020, the global Neoantigen Targeted Therapies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2029.

This report focuses on the global Neoantigen Targeted Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neoantigen Targeted Therapies development in United States, Europe and China.

Market Segmentation, Outlook & Regional Insights: Neoantigen Targeted Therapies Market

Segmentation by Product Type: Breakdown of data from year 2014 to 2020 and forecast until 2029:

 	
Monotherapy
 	
Combination Therapy

Segmentation by Application : Breakdown of data from year 2014 to 2020 and forecast until 2029:

 	
Medical Research Institution
 	
Hospital and Clinic
 	
Other

Market segment by Regions/Countries, this report covers

 	
United States
 	
Europe
 	
China
 	
Japan
 	
Southeast Asia
 	
Central & South America

Key Players, Recent Developments & Sector Viewpoints: Neoantigen Targeted Therapies Market

 	
Bavarian Nordic
 	
Genocea Biosciences
 	
Gradalis
 	
Immunicum
 	
Immunovative Therapies
 	
Iovance Biotherapeutics
 	
MediGene
 	
Neon Therapeutics

Key Insights Covered: Exhaustive Neoantigen Targeted Therapies Market

1. Market size (sales, revenue and growth rate) of Neoantigen Targeted Therapies industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Neoantigen Targeted Therapies industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Neoantigen Targeted Therapies industry.
4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2029 of Neoantigen Targeted Therapies industry.

Research Methodology: Neoantigen Targeted Therapies Market

 	
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
 	
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
 	
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.

Key Developments 

In Aug 2020, European Commission approves BLENREP (belantamab mafodotin) for the treatment of patients with relapsed and refractory multiple myeloma. GlaxoSmithKline plc today announced the European Commission has granted conditional marketing authorisation for BLENREP (belantamab mafodotin) as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. BLENREP is a first-in-class humanised anti-BCMA (B-cell maturation antigen) treatment for these patients whose disease has progressed despite the current standard of care.

Data demonstrated that treatment with single-agent BLENREP, administered as a 2.5 mg/kg dose every three weeks (Q3W), resulted in an overall response rate of 32%. The median duration of response was 11 months and median overall survival was 13.7 months.

The approval of BLENREP, with its novel mechanism of action, represents a new class of treatment that patients can turn to when their cancer stops responding to other standard of care options.

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple myeloma cells. BLENREP is an antibody drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa.

The US Food and Drug Administration approved BLENREP as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent, following a priority review for the company’s Biologics License Application.